On January 20, 2022, ONI, a biotechnology company democratizing the ability to observe single molecules in living cells with its desktop Nanoimager microscopy platform, announced the closing of a $75 million Series B funding round. The round was led by ARCH Venture Partners and Casdin Capital with participation from Section 32, ARTIS Ventures, Vertical Venture Partners, Axon Ventures, and private investors, including Paul Conley. Existing investors, including Oxford Science Enterprises, also participated in the round. Wilson Sonsini Goodrich & Rosati advised ONI on the transaction.

Proceeds from the financing will be used to grow ONI’s commercial and R&D teams in the U.S. and Asia, driving technology adoption in those geographies. Funds will also be used to expand ONI’s portfolio of consumables and cloud-based software apps to become end-to-end automated solutions for application verticals.

The Wilson Sonsini team that represented ONI in the transaction included:

Corporate
Daniel Glazer
Michael Labriola
Diviya Padman
Rui Ke
Abbie Currie

National Security
Michael Casey
Joshua Gruenspecht
John Lynch

For more information, please see ONI's press release.